Navigation Links
Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
Date:7/14/2010

tumors and that perifosine may have antitumor clinical activity as a single agent in neuroblastoma. Additionally, in a preclinical study recently published in the Journal of the National Cancer Institute, perifosine showed a statistically significant reduction in neuroblastoma cell survival, slowed or regressed tumor growth, and increased survival in mice bearing neuroblastoma tumors.

A decreased level of activated Akt was also observed in perifosine-treated neuroblastoma cells and xenograft tumors.

About Perifosine

Perifosine, a novel, potentially first-in-class, oral Akt inhibitor, is currently in Phase 3 trials in the United States for advanced colorectal cancer and multiple myeloma, under Special Protocol Assessment and Fast Track designation granted by the FDA for both indications. FDA has also granted perifosine orphan-drug designation for multiple myeloma and neuroblastoma. In Europe, the European Medicines Agency ("EMA") has issued positive Scientific Advice for perifosine in multiple myeloma and colorectal cancer, as well as positive opinion for Orphan Medicinal Product designation for perifosine in multiple myeloma.

Perifosine is also in a Phase 1 trial in pediatric patients, as well as in other Phase 1 and Phase 2 trials for several other tumor types.

About Orphan-Drug Designation

Orphan-drug designation is granted by the FDA Office of Orphan Drug Products to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity if the drug is the first of its type approved for the specified indication or if it demonstrates superior safety, efficacy, or a maj
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
2. Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
3. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
4. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
5. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
6. Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
7. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
8. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
9. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
11. AEterna Zentaris Announces Appointment of New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 30, 2014 In response to ... to address sales, training and consumer engagement challenges, ... innovative mobile applications to turn their clients’ visions ... latest customized mobile app creations, are now featured ... In partnership with Toyota, StudioPMG created a robust ...
(Date:10/1/2014)... The U.S. Department of Labor has ... Edwardsville as part of the Trade Adjustment Assistance Community ... co-administered by the Department of Labor and Department of ... Thomas E. Perez and Secretary of Education Arne Duncan ... grants to nearly 270 colleges across the country. ...
(Date:9/30/2014)... available in German . ... Mnchen (TUM) have demonstrated a new kind of building ... future computer chips could be based on three-dimensional arrangements ... enabling technology of the semiconductor industry CMOS fabrication ... researchers and collaborators at the University of Notre Dame ...
(Date:9/30/2014)... Sept. 30, 2014 Nematicide is a ... Nematodes are microscopic parasitic roundworms, found in massive ... other plants and animals. Nematicides have tended to ... properties promoting migration through the soil. A single ... plant-parasitic nematodes. With more than 10,000 species classified, ...
Breaking Biology Technology:Digital Agency Studio PMG Launches New Case Studies on Website 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2
... Calif. and MONROVIA, Calif., Jan. 6, 2011 Amgen ... today that they will collaborate to develop XmAb ® ... and CD32b.  XmAb5871 is currently in late-stage preclinical development ... Under the terms of the agreement, Amgen has the ...
... SAN FRANCISCO, Jan. 6, 2011 Vista Partners ... Therapeutics, Inc. (Nasdaq: OPXA ) and raised ... Silver, Principal Analyst at Vista Partners stated, "Opexa announced yesterday ... for the treatment of Multiple sclerosis , is now ...
... 6, 2011 BioInformatics, LLC announces the release of ... Technologies:  Market Insights for Life Science Suppliers (#10-005) This ... respond in a timely fashion to the rapidly changing ... LLC quantifies and characterizes the market for genetic analysis ...
Cached Biology Technology:Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 2Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 3Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Raises Target Price From $4.40 to $6.50 2BioInformatics, LLC New Market Report - Genomics Technologies 2
(Date:9/30/2014)... know what goes wrong with your muscles because of age, ... "normal" actually is. That,s where a new research report published ... Journal comes in. In the report, a team ... that can help scientists "see" which genes are active in ... never-before-detected gene activity and that men have approximately 400 more ...
(Date:9/30/2014)... release is available in German . ... their behavioural response to risky situations such as exposure ... Ornithology now found in a long-term study on different ... both metabolic rate and ambient temperature. High metabolic rates ... as in these scenarios birds were more likely to ...
(Date:9/30/2014)... a suite of perilous threats in today,s ocean. ... climate change, fragile coral ecosystems are disappearing at ... some species of corals surrounding the island of ... in their tropical environment: coral guard-crabs. New research ... Marine Station scientist Seabird McKeon and the museum,s ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Risky metabolism 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... , Jan. 24, 2013 /PRNewswire-iReach/ -- The companion diagnostics ... has become one of the most promising areas within ... companies are now entering the highly attractive market of ... developing a combination product. The explosive M&A trend in ...
... their mother,s diet during gestation and lactation were found to ... than those not exposed to the chemical, researchers at the ... BPA is a chemical most commonly found in the lining ... in many hard plastic bottles, including baby bottles, but many ...
... Researchers at the University of Pittsburgh School of ... key HIV protein. In findings published online today in ... this vulnerable spot could stop the virus from replicating, ... Previous research demonstrated that a small HIV protein ...
Cached Biology News:Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 2Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 3Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 4Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 5Female mice exposed to BPA by mothers show unexpected characteristics 2Female mice exposed to BPA by mothers show unexpected characteristics 3Pitt team finds 'Achilles Heel' of key HIV replication protein 2
Mouse monoclonal antibody to ALAS2 - aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)...
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
Mouse monoclonal antibody raised against a partial recombinant FBXO24. NCBI Entrez Gene ID = FBXO24...
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
Biology Products: